CII
AXDX

CR Intrinsic Investors’s Accelerate Diagnostics AXDX Stock Holding History

CR Intrinsic Investors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-18,224
Closed -$1.48M – 350
2013
Q2 		$1.48M Buy
+18,224
New +$1.35M 0.05% 295

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WIC
Wood Investment Counsel Denver, Colorado $669M AUM 20.44% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CR Intrinsic Investors's AXDX Position: Q3 2013 in Review

CR Intrinsic Investors sold out of Accelerate Diagnostics (AXDX) in Q3 2013, closing a stake of 18,224 shares — an estimated $1.48M sold.

CR Intrinsic Investors first reported a position in AXDX in Q2 2013 and held it in 1 quarter. The position peaked at $1.48M in Q2 2013. 47 funds tracked by Wall St. Rank hold AXDX as of Q3 2013.

  • CR Intrinsic Investors reported no remaining Accelerate Diagnostics position as of Q3 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 18,224 Accelerate Diagnostics shares in Q3 2013, an estimated $1.48M.
  • CR Intrinsic Investors first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's Accelerate Diagnostics position peaked at $1.48M in Q2 2013.
  • 47 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2013.

Based on CR Intrinsic Investors's 13F filing for Q3 2013, filed 14 Nov 2013.